Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-label, Fixed-Sequence, Drug-Drug Interaction Study Between Multiple Oral Doses of Inarigivir Soproxil and a Single Oral Dose of Midazolam in Healthy Subjects

Trial Profile

A Phase 1, Open-label, Fixed-Sequence, Drug-Drug Interaction Study Between Multiple Oral Doses of Inarigivir Soproxil and a Single Oral Dose of Midazolam in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 Jan 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Inarigivir soproxil (Primary) ; Midazolam
  • Indications Dengue; Hepatitis B; Hepatitis C; Japanese encephalitis; Norovirus infections; Respiratory syncytial virus infections; West Nile virus infections
  • Focus Pharmacokinetics
  • Sponsors Spring Bank Pharmaceuticals
  • Most Recent Events

    • 12 Apr 2019 According a Spring Bank Pharmaceuticals media release, data from this trial announced at The International Liver Congress (ILC), the 2019 Annual Meeting of the European Association for the Study of the Liver (EASL).
    • 12 Apr 2019 Results presented in a Spring Bank Pharmaceuticals media release.
    • 04 Sep 2018 Status changed to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top